Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
Paripati
H
H
Stewart
A K
AK
Cabou
S
S
Dueck
A
A
Zepeda
V J
VJ
Pirooz
N
N
Ehlenbeck
C
C
Reeder
C
C
Slack
J
J
Leis
J F
JF
Boesiger
J
J
Torloni
A S
AS
Fonseca
R
R
Bergsagel
P L
PL
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012074:Remission Induction; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide